Clinical trial
Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial…
NCT00171236 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00171236 |
|---|---|
| Title | Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia |
| Official title | Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Heterozygous Familial Hypercholesterolemia, Mixed Dyslipidemia |
| Intervention type | Drug |
| Interventions | Fluvastatin |
| Enrollment | 84 |
| Start date | Oct 1, 2001 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Sep 15, 2005 |
| Last update posted | Nov 8, 2011 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: